- Increased gastrointestinal adverse events (nausea, vomiting, diarrhea) were the most consistent findings.
- Possible reductions in serious infections and respiratory disease were observed.
- Pancreatitis and biliary disease signals remain inconclusive.
- Neurologic and psychiatric associations showed low-certainty signals only.
- Overall evidence for noncardiometabolic outcomes was low certainty.
Source: JAMA Network Open
